Krsnaa Diagnostics Limited reported a consolidated net profit of ₹1,014.31 million for the financial year ended March 31, 2026, a 31% increase compared to the previous year. Revenue from operations for FY26 stood at ₹7,727.74 million, up from ₹7,171.60 million in FY25. The reported PAT includes a fair valuation gain of ₹222.41 million from the investment in Apulki Healthcare Private Limited. The board has recommended a final dividend of ₹2 per equity share, representing 40% of the face value, subject to shareholder approval.

Financial Performance

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹417.18 million on revenue from operations of ₹1,926.04 million, compared to a net profit of ₹206.78 million on revenue of ₹1,860.76 million in the corresponding quarter of the previous year. EBITDA for the quarter stood at ₹549 million versus ₹530 million in the same period last year, while the EBITDA margin came in at 29% compared to 29% year-on-year.

The following table summarises the key quarterly and full-year financial metrics:

Operational Highlights and Expansion

Operating cash flows strengthened significantly to ₹1,430.98 million in FY26 compared to ₹873.27 million in FY25. The retail diagnostics vertical, Krsnaa Retail Private Limited, delivered an 8 times jump in revenue and a 7 times surge in touchpoints, expanding to 3,500 locations across 5 states. A total of 51 centers and 1,167 collection centers were operationalized in FY25-26. The company projects that upon completion of its existing order book, it will have 200+ CT/MRI centres, cementing its position as one of Asia’s largest radiology players.

The Rajasthan project is expected to grow the network to 7 Reference Labs, 41 Mother Labs, 249 Satellite Labs & 5,000+ Collection Centres. Total assets as of March 31, 2026, stood at ₹18,237.16 million, compared to ₹12,815.95 million in the previous year.

Auditor and Regulatory Disclosures

The Statutory Auditors, MSKA & Associates LLP, issued an unmodified opinion on the audited standalone and consolidated financial results. The auditor's report included an emphasis of matter regarding assessment orders passed by the Income Tax Authorities for assessment years 2017-18 to 2023-24 under search assessment proceedings, resulting in a demand of ₹626.90 million. The company has filed appeals and deposited ₹102.77 million under protest, with management stating the demand is not tenable and not expected to have a material impact.

The board approved the re-appointment of M/s Kirtane & Pandit LLP as Statutory Auditors for FY27 to FY31, subject to shareholder approval.

Krsnaa Diagnostics Limited has disclosed that it has received income tax assessment orders and demand notices amounting to Rs. 11,30,54,699 for the assessment years 2018-19 and 2019-20. The orders were issued by the Assistant Commissioner of Income Tax, Pune, under section 144 read with Section 147 and demand notices under Section 156 of the Income Tax Act, 1961.

The disclosure follows a search conducted by Income Tax Authorities on the company's premises under section 132 of the Income Tax Act, which was previously intimated on July 29, 2022. The company noted that the matter was being handled by external tax consultants, and the requirement for disclosure was identified during a subsequent internal compliance review.

Details of the Demand

The annexure provided to the exchanges details the specific financial implications of the orders. The aggregate demand is split between the two assessment years, comprising both tax and interest components.

The due date for payment is 30 days from the date of service of the demand notice, as per Section 156 of the Income Tax Act.

Company Response and Impact

Krsnaa Diagnostics has confirmed that it has already challenged the orders before the appropriate appellate and judicial forums. Management expressed confidence in defending the matter based on the facts and merits of the case.

Regarding the financial impact, the company stated that the demand represents an aggregate contingent liability of Rs. 11,30,54,699/-. Provisioning under Ind AS 37 is currently being evaluated. The company further clarified that there is no operational disruption resulting from these proceedings.